CN Patent

CN116459255A — 氘代右美沙芬与安非他酮联合在制备ad激越的药物中的用途

Assigned to Shenzhen Salubris Pharmaceuticals Co Ltd · Expires 2023-07-21 · 3y expired

What this patent protects

本发明属于药物组合应用技术领域，具体涉及一种药物组合物的新药物用途，具体涉及一种氘代右美沙芬或其药用盐与安非他酮或其药用盐联合在制备AD激越的药物中的用途。

USPTO Abstract

本发明属于药物组合应用技术领域，具体涉及一种药物组合物的新药物用途，具体涉及一种氘代右美沙芬或其药用盐与安非他酮或其药用盐联合在制备AD激越的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number: CN116459255A
Jurisdiction: CN
Classification: —
Expires: 2023-07-21
Drug substance claim: No
Drug product claim: No
Assignee: Shenzhen Salubris Pharmaceuticals Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.